Brain derived neurotrophic factor (BDNF) is a growth factor for neurons. Discovered in 1982 in samples of brain tissue from pigs, the growth factor has been shown to promote survival, growth, development and plasticity of nerve cells (Barde 1982, Huang 2001).
Since its discovery, interest about the effects of BDNF on health and disease has only grown.
BDNF has widespread distribution in the brain, including in the hippocampus, amygdala, cerebellum and cerebral cortex both during early development and in adults (Huang 2001, Miranda 2019). As the hippocampus is important in memory function, the presence of BDNF has been shown to be a critical factor in the storage and persistence of long-term memories (Bekinschtein 2008).
The Biochemistry of BDNF
The activity of BDNF is somewhat complex. Initially, the compound is synthesized as the precursor molecule proBDNF. Inside neurons, some of the proBDNF is cleaved into BDNF, although both molecules are released from cells (Pang 2004). Interestingly, proBDNF and BDNF appear to have opposing functions. ProBDNF binds to the p75 neurotrophin receptor also referred to as the low-affinity nerve growth factor receptor. ProBDNF binding causes depression of neuronal functioning and induces apoptosis or cell death (Woo 2005, Friedman 2010). In opposition, mature BDNF binds to tyrosine kinase receptors (TrkB) where it increases neuronal survival, induces memory formation and stimulates neuroplasticity (McAllister 1999). As such, the balance of effects from BDNF is reliant, at least in part, on the ratio of proBDNF to BDNF.
BDNF in Brain Pathologies
With such a crucial role in supporting neuronal health and function, it’s not surprising BDNF is involved in a number of different pathologies. Evidence suggests low BDNF plays a role in depression, anxiety disorders, bipolar and schizophrenia (Molendijk 2014, Suliman 2013, Fernandes 2015, Bora 2019). In addition, neurodegenerative conditions, like Alzheimer’s dementia and Parkinson’s disease also have links with lowered BDNF levels and activity (Ng 2019, Rahmani 2019).
Early evidence on the ratio between proBDNF and BDNF indicates that it may play a role in a number of these conditions as well, although research is ongoing (Wang 2021). Increasing the proteolytic cleavage of proBDNF into BDNF may be therapeutic in some conditions associated with low BDNF activity.
Lithium and BDNF
It has been well documented that lithium has benefits for bipolar disorder, as an adjunctive treatment in depression and possible benefits in Alzheimer’s dementia (Kishi 2020, Nelson 2014, Damri 2020). Currently, there are suggestions that lithium may help Parkinson’s pathology as well (Guttuso 2019). At least part of the reason lithium has benefits in these conditions is likely from its effects on BDNF.
Clinical studies on lithium have shown increases in serum BDNF levels with its use in bipolar disorder (Tunca 2014, de Sousa 2011) and Alzheimer’s dementia (Leyhe 2009). While some of the human research has been mixed, animal studies also suggest that lithium exerts its benefits upon controlling mania through increased BDNF production (Gideons 2017).
Lithium’s Actions on BDNF
The potential mechanisms for how lithium increases BDNF are somewhat complex. Lithium has effects on adenyl cyclase enzymes and production of cyclic adenosine monophosphate (cAMP). Lithium increases adenyl cyclase overall, but decreases stimulated adenyl cyclase activity. The end result is that lithium increases and stabilizes cAMP levels (Manji 2000). Increased cAMP levels increase protein kinase A, an enzyme that phosphorylates and activates numerous other molecules and enzymes including the transcription factor cAMP response element binding protein (CREB). When activated through phosphorylation, CREB increases BDNF transcription and production (Zheng 2011).
Promoter exons are portions of a gene that promote its transcription making more of the targeted protein. The BDNF gene has several promoter exons and research in rats suggests that lithium upregulates the function of promoter exon IV. Animal studies have shown that a two millimolar concentration of lithium effectively doubles the expression of the promoter exon (Dwivedi 2015, Yasuda 2009).
Through increased BDNF production, lithium may enhance neurogenesis, nerve cell growth and survival and neural plasticity. These effects likely explain at least part of the therapeutic effects seen with its use.
Lithium has well documented benefits for the brain. At least some of these benefits are likely mediated through lithium’s effects on BDNF production. With further research, we may better understand lithium’s benefits on mental health, allowing even more targeted use for improving and preserving brain function.
Barde YA, Edgar D, Thoenen H. Purification of a new neurotrophic factor from mammalian brain. EMBO J. 1982;1(5):549-553.
Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci. 2001;24:677-736. doi:10.1146/annurev.neuro.24.1.677
Miranda M, Morici JF, Zanoni MB, Bekinschtein P. Brain-Derived Neurotrophic Factor: A Key Molecule for Memory in the Healthy and the Pathological Brain. Front Cell Neurosci. 2019;13:363. Published 2019 Aug 7. doi:10.3389/fncel.2019.00363
Bekinschtein P, Cammarota M, Katche C, et al. BDNF is essential to promote persistence of long-term memory storage. Proc Natl Acad Sci U S A. 2008;105(7):2711-2716. doi:10.1073/pnas.0711863105
Pang PT, Teng HK, Zaitsev E, et al. Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity. Science. 2004;306(5695):487-491. doi:10.1126/science.1100135
Woo NH, Teng HK, Siao CJ, et al. Activation of p75NTR by proBDNF facilitates hippocampal long-term depression. Nat Neurosci. 2005;8(8):1069-1077. doi:10.1038/nn1510
Friedman WJ. Proneurotrophins, seizures, and neuronal apoptosis. Neuroscientist. 2010;16(3):244-252. doi:10.1177/1073858409349903
McAllister AK, Katz LC, Lo DC. Neurotrophins and synaptic plasticity. Annu Rev Neurosci. 1999;22:295-318. doi:10.1146/annurev.neuro.22.1.295
Molendijk ML, Spinhoven P, Polak M, Bus BA, Penninx BW, Elzinga BM. Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N=9484). Mol Psychiatry. 2014;19(7):791-800. doi:10.1038/mp.2013.105
Suliman S, Hemmings SM, Seedat S. Brain-Derived Neurotrophic Factor (BDNF) protein levels in anxiety disorders: systematic review and meta-regression analysis. Front Integr Neurosci. 2013;7:55. Published 2013 Jul 29. doi:10.3389/fnint.2013.00055
Fernandes BS, Molendijk ML, Köhler CA, et al. Peripheral brain-derived neurotrophic factor (BDNF) as a biomarker in bipolar disorder: a meta-analysis of 52 studies. BMC Med. 2015;13:289. Published 2015 Nov 30. doi:10.1186/s12916-015-0529-7
Bora E. Peripheral inflammatory and neurotrophic biomarkers of cognitive impairment in schizophrenia: a meta-analysis. Psychol Med. 2019;49(12):1971-1979. doi:10.1017/S0033291719001685
Ng TKS, Ho CSH, Tam WWS, Kua EH, Ho RC. Decreased Serum Brain-Derived Neurotrophic Factor (BDNF) Levels in Patients with Alzheimer’s Disease (AD): A Systematic Review and Meta-Analysis. Int J Mol Sci. 2019;20(2):257. Published 2019 Jan 10. doi:10.3390/ijms20020257
Rahmani F, Saghazadeh A, Rahmani M, et al. Plasma levels of brain-derived neurotrophic factor in patients with Parkinson disease: A systematic review and meta-analysis. Brain Res. 2019;1704:127-136. doi:10.1016/j.brainres.2018.10.006
Kishi T, Ikuta T, Matsuda Y, et al. Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials [published online ahead of print, 2020 Nov 11]. Mol Psychiatry. 2020;10.1038/s41380-020-00946-6. doi:10.1038/s41380-020-00946-6
Nelson JC, Baumann P, Delucchi K, Joffe R, Katona C. A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression. J Affect Disord. 2014;168:269-275. doi:10.1016/j.jad.2014.05.053
Damri O, Shemesh N, Agam G. Is There Justification to Treat Neurodegenerative Disorders by Repurposing Drugs? The Case of Alzheimer’s Disease, Lithium, and Autophagy. Int J Mol Sci. 2020;22(1):189. Published 2020 Dec 27. doi:10.3390/ijms22010189
Guttuso T Jr, Andrzejewski KL, Lichter DG, Andersen JK. Targeting kinases in Parkinson’s disease: A mechanism shared by LRRK2, neurotrophins, exenatide, urate, nilotinib and lithium. J Neurol Sci. 2019;402:121-130. doi:10.1016/j.jns.2019.05.016
Tunca Z, Ozerdem A, Ceylan D, Yalçın Y, Can G, Resmi H, Akan P, Ergör G, Aydemir O, Cengisiz C, Kerim D. Alterations in BDNF (brain derived neurotrophic factor) and GDNF (glial cell line-derived neurotrophic factor) serum levels in bipolar disorder: The role of lithium. J Affect Disord. 2014 Sep;166:193-200. doi: 10.1016/j.jad.2014.05.012. Epub 2014 May 22. PMID: 25012431.
de Sousa RT, van de Bilt MT, Diniz BS, et al. Lithium increases plasma brain-derived neurotrophic factor in acute bipolar mania: a preliminary 4-week study. Neurosci Lett. 2011;494(1):54-56. doi:10.1016/j.neulet.2011.02.054
Leyhe T, Eschweiler GW, Stransky E, et al. Increase of BDNF serum concentration in lithium treated patients with early Alzheimer’s disease. J Alzheimers Dis. 2009;16(3):649-656. doi:10.3233/JAD-2009-1004
Gideons ES, Lin PY, Mahgoub M, Kavalali ET, Monteggia LM. Chronic lithium treatment elicits its antimanic effects via BDNF-TrkB dependent synaptic downscaling. Elife. 2017;6:e25480. Published 2017 Jun 16. doi:10.7554/eLife.25480
Manji HK, Lenox RH. Signaling: cellular insights into the pathophysiology of bipolar disorder. Biol Psychiatry. 2000;48(6):518-530. doi:10.1016/s0006-3223(00)00929-x
Zheng F, Zhou X, Luo Y, Xiao H, Wayman G, Wang H. Regulation of brain-derived neurotrophic factor exon IV transcription through calcium responsive elements in cortical neurons. PLoS One. 2011;6(12):e28441. doi:10.1371/journal.pone.0028441
Dwivedi T, Zhang H. Lithium-induced neuroprotection is associated with epigenetic modification of specific BDNF gene promoter and altered expression of apoptotic-regulatory proteins. Front Neurosci. 2015;8:457. Published 2015 Jan 14. doi:10.3389/fnins.2014.00457
Yasuda S, Liang MH, Marinova Z, Yahyavi A, Chuang DM. The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons. Mol Psychiatry. 2009;14(1):51-59. doi:10.1038/sj.mp.4002099